Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines Ltd shows a promising financial outlook, primarily due to the strong preference for its leading product Brukinsa among oncologists, which is projected to significantly contribute to peak sales of approximately $7.1 billion. The company's innovative asset, sonrotoclax, emerges as the most advanced BCL2 inhibitor, with expectations of surpassing the performance of competitors, bolstering potential revenue streams, including estimated peak sales of $3.4 billion. Furthermore, BeOne Medicines anticipates robust growth, exceeding 40% year-over-year into 2025, with plans for profitable operations and positive free cash flow expected to materialize by that same year.

Bears say

BeOne Medicines Ltd faces a negative outlook primarily due to several fundamental challenges that could significantly impact its financial performance. The potential for slower-than-expected uptake of its products, combined with the risk of unsuccessful pipeline programs and adverse regulatory outcomes, could lead to diminished commercial viability and a substantial decrease in stock value. Additionally, being positioned within a crowded oncology market coupled with high cash burn on its research pipeline raises concerns about the company’s ability to develop marketable drugs, further diminishing investor confidence.

BeiGene Ltd (ONC) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 10 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $384.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $384.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.